Ausgabe Sonderheft 1/2017
Therapy assessment with PET in cancer patients
Inhalt (11 Artikel)
Therapy monitoring with PET in cancer patients: achievements, opportunities and challenges ahead for the PET community
Nicolas Aide, Stefano Fanti
Quantification, improvement, and harmonization of small lesion detection with state-of-the-art PET
Charlotte S. van der Vos, Daniëlle Koopman, Sjoerd Rijnsdorp, Albert J. Arends, Ronald Boellaard, Jorn A. van Dalen, Mark Lubberink, Antoon T. M. Willemsen, Eric P. Visser
EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies
Nicolas Aide, Charline Lasnon, Patrick Veit-Haibach, Terez Sera, Bernhard Sattler, Ronald Boellaard
Using PET for therapy monitoring in oncological clinical trials: challenges ahead
C. M. Deroose, S. Stroobants, Y. Liu, L. K. Shankar, P. Bourguet
Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician
S. Lheureux, C. Denoyelle, P. S. Ohashi, J. S. De Bono, F. M. Mottaghy
Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments
Katja Pinker, Christopher Riedl, Wolfgang A. Weber
The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy
Annie N. M. Wong, Grant A. McArthur, Michael S. Hofman, Rodney J. Hicks
Therapy assessment in prostate cancer using choline and PSMA PET/CT
Francesco Ceci, Ken Herrmann, Boris Hadaschik, Paolo Castellucci, Stefano Fanti
Therapy assessment of bone metastatic disease in the era of 223radium
Elba Etchebehere, Ana Emilia Brito, Alireza Rezaee, Werner Langsteger, Mohsen Beheshti
FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
Sally F. Barrington, Regine Kluge